NCT04582539 2025-10-22
LIMBER
Incyte Corporation
Phase 1/2 Terminated
Clinical Trials
24 trialsNCT01284348 2024-08-29
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT02065869 2023-09-29
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT03733249 2023-09-26
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT00931606 2023-09-13
MK-7962-012
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00858364 2022-11-30
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Amgen
Phase 3 Terminated
NCT01100879 2022-05-09
AOC-MM
Vifor Pharma
Phase 4 Terminated
NCT02055781 2021-11-18
PAC326
CTI BioPharma
Phase 3 Terminated
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT00495378 2016-12-20
RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia
Ortho Biotech Products, L.P.
Phase 4 Terminated
NCT02608060 2016-11-02
A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B
Hoffmann-La Roche
Phase 4 Terminated
NCT02624141 2016-11-02
A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy
Hoffmann-La Roche
Phase 4 Terminated
NCT00702702 2014-08-21
Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00785356 2014-08-21
Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids
Repros Therapeutics Inc.
Phase 3 Terminated
NCT00989092 2014-01-29
Darbepoetin Alfa and Anemia of Cancer
Amgen
Phase 2 Terminated
NCT00386152 2013-07-19
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00629876 2011-12-01
A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.
Takeda
Phase 1 Terminated
NCT00210730 2011-06-10
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00246597 2011-05-19
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00350090 2011-05-19
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00306267 2011-05-18
A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00083434 2011-04-27
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00083486 2011-04-27
Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00119600 2009-05-11
A Study of AMG 114 Administered by Subcutaneous Injection for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies Receiving Multicycle Chemotherapy
Amgen
Phase 1/2 Terminated